A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease Save

Date Added
October 10th, 2017
PRO Number
Pro00069773
Researcher
Roberto Pisoni

Silhouette
Keywords
Diabetes, Kidney
Summary

If you are an adult with type 2 diabetes mellitus and diabetic kidney disease, you may be eligible to take part in a clinical research study.
The purpose of this study is to find out if an investigational drug called finerenone slows the progression of diabetic kidney disease. Qualified participants will be randomly assigned to take either finerenone by mouth or placebo (inactive pill). Study medication, study visits, blood work and study procedures will be provided free of charge.

Institution
MUSC
Recruitment Contact
Lori Spillers
843-792-8166
spillerl@musc.edu

Change_preferences

-- OR --

Create_login